Sidath Katugampola

Sidath Katugampola has accumulated extensive work experience in the field of biomarker development and translational medicine. Sidath is currently serving as the Executive Director of Clinical Biomarkers and Translational Medicine at Exscientia, starting in July 2022. Prior to this, they held the position of Director of Biomarker and Translational Medicine at UCB from September 2018 to June 2022. Before joining UCB, Sidath worked at Cancer Research UK (CRUK) as a Biomarker Development Specialist from July 2012 to September 2018 and as a Drug Development Project Manager from November 2011 to August 2012. Sidath also gained valuable experience at Pfizer Pharmaceuticals, where they held various roles including Biology Leader, Principal Scientist, Biomarker and Translational Sciences Team Leader, Mechanistic Safety Pharmacologist, and Pharmacologist from 2001 to 2011.

Sidath Katugampola earned a PhD in Physiology, Pharmacology, and Biochemistry from the University of Cambridge, where they attended from 1998 to 2001. There is no information available regarding their education prior to or after this period.